

## Supporting Information


### Ring-Closing Metathesis of Peptides in Water

Stephen A. Cochrane, Zedu Huang and John C. Vederas\*

Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada, T6G 2G2

\*To whom correspondence should be addressed. Email: [john.vederas@ualberta.ca](mailto:john.vederas@ualberta.ca)

#### Synthesis of Fmoc-L-Sac-OH




*S*-allyl-L-cysteine (Sac) (2.00 g, 12.4 mmol) and NaHCO<sub>3</sub> (3.13 g, 37.2 mmol) were dissolved in water (60 mL) and stirred at room temperature. A solution of FmocOSu (4.59 g, 13.6 mmol) in THF (60 mL) was then added to the aqueous solution and stirring was continued for an additional 2 hours at room temperature. The reaction mixture was acidified to pH 1 with 6 M HCl and extracted with EtOAc (4 x 30 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated *in vacuo* and purified by flash chromatography (silica gel, 97:2:1 CH<sub>2</sub>Cl<sub>2</sub> : *i*-PrOH : AcOH), yielding Fmoc-L-Sac-OH as a white solid (1.30 g, 27%). [ $\alpha$ ]<sub>D</sub> -12.2° (*c* 1.00, CH<sub>2</sub>Cl<sub>2</sub>); IR (CHCl<sub>3</sub> cast) 3325, 3065, 1685, 1532 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz):  $\delta$  7.77 (d, 2H, *J* = 7.6 Hz, Fmoc-H), 7.62-7.60 (m, 2H, Fmoc-H), 7.40 (t, 2H, *J* = 7.4 Hz, Fmoc-H), 7.31 (t, 2H,


$J = 7.5$  Hz, Fmoc-H), 5.76-5.73 (m, 1H,  $\text{CH}=\text{CH}_2$ ), 5.64 (d, 1H,  $J = 7.8$  Hz, NH), 5.13 (m, 2H,  $\text{CH}=\text{CH}_2$ ), 4.60-4.66 (m, 1H, Cys- $\text{H}_\alpha$ ), 4.44-4.46 (m, 2H, Fmoc  $\text{CHCH}_2$ ), 4.24 (1H, t,  $J = 7.1$  Hz, Fmoc  $\text{CHCH}_2$ ), 3.15 (2H, d,  $J = 7.1$  Hz,  $\text{CH}_2\text{CH}=\text{CH}_2$ ), 3.04 (dd, 1H,  $J = 14.2, 4.5$ , Cys- $\text{H}_\beta$ ), 2.94 (dd, 1H,  $J = 14.0, 4.5$  Hz, Cys- $\text{H}_\beta$ );  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz):  $\delta$  175.4, 155.9, 143.6 (d, rotamers), 141.3, 133.5, 127.8, 127.1, 125.0, 120.0, 118.2, 67.4, 53.4, 47.1, 35.3, 32.5; HRMS (ES) Calcd for  $\text{C}_{21}\text{H}_{21}\text{NO}_4\text{SNa}[\text{M}+\text{Na}]^+$  406.1083, found 406.1079.

### Elucidation of the structure of the +14 Da side product:



Comparison of the LC MS/MS spectra of the isolated +14 Da side product and a 1-Pip-6-Pgl-oxytocin standard (synthesized by SPPS) reveals they are identical. The extracted mass chromatograms of the +14 Da side product (37.09 mins) and the synthetic standard (36.80 mins) are also very similar. These results led us to propose that 1-Pip-6-Pgl-oxytocin **3k** is the +14 Da side product:



### Extracted Mass Chromatograms:



LC MS/MS spectra:



## Summary of RCM experiments:


**Table 1.** RCM of peptide analogues on-resin and in aqueous solution.

Peptide	System								
	Resin			30 % <i>t</i> -BuOH			Micelles		
	HGII (equiv)	Time (h)	Yield (%) <sup>a</sup>	HGII (equiv)	Time (h)	Yield (%) <sup>b</sup>	HGII (equiv)	Time (h)	Yield (%) <sup>b</sup>
<b>3a</b>	0.2	24	50	50	24	0	50	24	0
<b>3b</b>	0.2	24	100	50	24	< 1	20	24	0
<b>3c</b>	0.2	24	100	50	24	< 1	20	24	0
<b>3d</b>	0.2	24	100	0.5	3	78	50	24	0
<b>3e</b>	0.2	24	0	10	24	0	20	24	0
<b>4a</b>	0.2	24	0	50	24	0	50	24	0
<b>4b</b>	0.2	24	0	50	24	< 1	50	24	0
<b>4c</b>	0.2	24	0	50	24	< 1	20	24	0
<b>4d</b>	0.2	24	0	0.5	24	63	20	24	0
<b>4e</b>	0.2	24	0	10	24	0	20	24	0


All aqueous reactions were conducted at 37 °C with 5000 equiv MgCl<sub>2</sub>. A concentration of 0.1 mM peptide or less was necessary for the large excess of salt to dissolve. (a) Yields of the on-resin RCM reactions were calculated from the ratio of cyclic products to linear starting material by HPLC integration; (b) isolated yields.

## HPLC Traces:


### 1,6-Agl-oxytocin (3a)




### 1,6-Pgl-oxytocin (3b)




### 1,6-Oas-oxytocin (3c)




### 1,6-Sac-oxytocin (3d)




### Fmoc-1,6-Sac-oxytocin (3d')




### 1,6-X-oxytocin (3e)




### 7,14-Agl-crotalphine (4a)




### 7,14-Pgl-crotalphine (4b)




### 7,14-Oas-crotalphine (4c)




### 7,14-X-crotalphine (4e)




### Cyclized *cis*-1,6-Agl-Oxytocin (3f)




### Cyclized *trans*-1,6-Agl-Oxytocin (3g)




### Cyclized 1,6-Pgl-oxytocin (3h)




### Cyclized 1,6-Oas-Oxytocin (3i)




### Cyclized 1,6-Sac-oxytocin (3j)




### Cyclized Fmoc-1,6-Sac-oxytocin (3j')




### 1-Pip-6-Pgl-oxytocin (3k)




### Cyclized 7,14-Oas-crotalphine (4g)



### Cyclized 7,14-Pgl-crotalphine (4h)




### Cyclized 7,14-Sac-crotalphine (4i)




## MALDI-TOF Spectra:

### 1,6-Agl-oxytocin (3a)




L:\\_run1\_0004.dat  
Acquired: 09:23:00, June 13, 2011

### 1,6-Pgl-oxytocin (3b)




L:\\_pureHPLCfraction\_0001.dat  
Acquired: 02:08:00, November 17, 2011

### 1,6-Oas-oxytocin (3c)




L:\\_HPLCfraction\_0001.dat  
Acquired: 01:54:00, November 14, 2011

### 1,6-Sac-oxytocin (3d)




..\_lpureHPLCfraction\_0001.dat  
Acquired: 00:24:00, November 15, 2011

### Fmoc-1,6-Sac-oxytocin (3d')




L1\_1\F6\_0002.dat  
Acquired: 16:58:00, March 14, 2012

### 1,6-X-oxytocin (3e)



### 7,14-Agl-crotalphine (4a)




Cro-ana-with-allylGly  
L1\_1\Cro-ana-with-allylGly\_0001.dat  
Acquired: 18:01:00, June 09, 2011

[M-H]<sup>-</sup>

S24

### 7,14-Pgl-crotalphine (4b)




L1:\BishomoGly-cro-run-1-3\_0001.dat  
Acquired: 05:56:00, December 30, 2011

[M-H]<sup>-</sup>

S25

### 7,14-Oas-crotalphine (4c)




L1:\Ser-alyt-Cro-1-0001.dat  
Acquired: 06:43:00, December 26, 2011

$[M+Na]^+$

S26

### 7,14-Sac-crotalphine (4d)




L1...Allyl-Cys-cro-1-2-pos\_0001.dat  
Acquired: 02:25:00, November 29, 2011

[M-H]<sup>-</sup>

S27


### 7,14-X-crotalphine (4e)



L1\_1\_Novel-Cys-Cro-July-12\_0001.dat  
Acquired: 11:38:00, July 12, 2012


$[M+H]^+$

Cyclized *cis*- and *trans*-1,6-Agl-oxytocin (3f, 3g)



$[M+H]^+$

### Cyclized 1,6-Pgl-oxytocin (3h)




L1\_1\F2: 0001.dat  
Acquired: 03:22:00, January 18, 2012

$[M+H]^+$

S30

$[M+Na]^+$   
Cyclized  $\beta$ -Oas-oxytocin (3i)




L1\_1\F4\_0001.dat  
Acquired: 11:20:00, April 03, 2012

[M+H]<sup>+</sup>

S31

### Cyclized 1,6-Sac-oxytocin (3j)

Voyager Spec #1=>AdvBC(32,0.5,0.1)=>BC[BP = 1061.1, 16622]




..\_1\F10\_0001.dat  
Acquired: 09:14:00, June 11, 2012

[M+Na]<sup>+</sup>

S32

### Cyclized Fmoc-1,6-Sac-oxytocin (3j')




L1...HPLCfraction26mins\_0001.dat  
Acquired: 19:35:00, February 29, 2012

[M+H]<sup>+</sup>

**1-Pip-6-Pgl-oxytocin (3k)**

[M+Na]<sup>+</sup>

Voyager Spec #1 [BP = 1039.4, 24387]




L1\_1pureHPLCfraction\_0001.dat  
Acquired: 00:05:00, February 15, 2012

[M-H]<sup>-</sup>

S34

### Cyclized 7,14-Pgl-crotalphine (4h)




L1\_115-good 0001.dat  
Acquired: 15:16:00, April 02, 2012

$[M+H]^+$

S35

### Cyclized 7,14-Oas-crotalphine (4i)




L1...cyclic-AllylSer-Cro-pos-good\_0001.dat  
Acquired: 18:59:00, April 05, 2012

[M-H]<sup>-</sup>



S36


### Cyclized 7,14-Sac-crotalphine (4j)





L1\_1150312-ZeduSallyfrnmg\_0001.dat  
Acquired: 11:32:00, March 16, 2012


S37








S39





S41














S46





S47







S49












S53







S56



S57

